Omeros Corporation (NASDAQ:OMER) — Market Cap & Net Worth
Market Cap & Net Worth: Omeros Corporation (OMER)
Omeros Corporation (NASDAQ:OMER) has a market capitalization of $851.51 Million ($851.51 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9848 globally and #2536 in its home market, demonstrating a 11.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Omeros Corporation's stock price $15.06 by its total outstanding shares 70900459 (70.90 Million). Analyse OMER cash generation efficiency to see how efficiently the company converts income to cash.
Omeros Corporation Market Cap History: 2015 to 2026
Omeros Corporation's market capitalization history from 2015 to 2026. Data shows growth from $1.12 Billion to $1.07 Billion (1.58% CAGR).
Index Memberships
Omeros Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #266 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #987 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.05% | #157 of 263 |
Weight: Omeros Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Omeros Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Omeros Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.04x
Omeros Corporation's market cap is 5.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.12 Billion | $13.51 Million | -$75.10 Million | 82.56x | N/A |
| 2016 | $703.33 Million | $41.62 Million | -$66.75 Million | 16.90x | N/A |
| 2017 | $1.38 Billion | $64.83 Million | -$53.48 Million | 21.25x | N/A |
| 2018 | $789.83 Million | $29.87 Million | -$126.76 Million | 26.44x | N/A |
| 2019 | $998.99 Million | $111.81 Million | -$84.49 Million | 8.94x | N/A |
| 2020 | $1.01 Billion | $73.81 Million | -$138.06 Million | 13.72x | N/A |
| 2021 | $455.89 Million | $90.52 Million | -$111.41 Million | 5.04x | N/A |
Competitor Companies of OMER by Market Capitalization
Companies near Omeros Corporation in the global market cap rankings as of May 4, 2026.
Key companies related to Omeros Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Omeros Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Omeros Corporation's market cap moved from $1.12 Billion to $ 1.07 Billion, with a yearly change of 1.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.07 Billion | -12.31% |
| 2025 | $1.22 Billion | +73.84% |
| 2024 | $700.50 Million | +202.14% |
| 2023 | $231.84 Million | +44.69% |
| 2022 | $160.24 Million | -64.85% |
| 2021 | $455.89 Million | -54.99% |
| 2020 | $1.01 Billion | +1.38% |
| 2019 | $998.99 Million | +26.48% |
| 2018 | $789.83 Million | -42.67% |
| 2017 | $1.38 Billion | +95.87% |
| 2016 | $703.33 Million | -36.94% |
| 2015 | $1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Omeros Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $851.51 Million USD |
| MoneyControl | $851.51 Million USD |
| MarketWatch | $851.51 Million USD |
| marketcap.company | $851.51 Million USD |
| Reuters | $851.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more